Effective control of mucosal and systemic inflammation is central to reducing arrhythmogenic risk in IBD, as proinflammatory cytokines, notably TNF-alpha and IL-6, modulate cardiac electrophysiology by altering calcium handling and connexin-mediated conduction, increasing atrial excitability and conduction heterogeneity [35]. This evidence concerns the gene IL6 and inflammatory bowel disease.